Use of new once-daily 5-aminosalicylic acid preparations in the treatment of ulcerative colitis:Is there anything new under the sun?

作     者：Peter Laszlo Lakatos 

作者机构：1st Department of MedicineSemmelweis University 

出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)

年 卷 期：2009年第15卷第15期

页      面：1799-1804页

核心收录：

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

主　　题：Ulcerative colitis 5-aminosalicylate Mesalazine Multi matrix system Therapy Once-daily Compliance 

摘      要：5-aminosalicylate(5-ASA)agents remain the mainstay treatment in ulcerative colitis(UC).A number of oral 5-ASA agents are commercially available,including azobond pro-drugs,as well as delayed-and controlledrelease forms of ***,poor adherence due to frequent daily dosing and a large number of tablets has been shown to be an important barrier to successful management of patients with ***, new,once-daily formulations of mesalazine,including the unique multi-matrix delivery system and mesalazine granules,were proven to be efficacious in inducing and maintaining remission in mild-to-moderate UC,with a good safety profile comparable to that of other oral mesalazine *** addition,they offer the advantage of a low pill burden and might contribute to increased long-term compliance and treatment success in clinical *** editorial summarizes the available literature on the short-and medium-term efficacy and safety of the new once-daily mesalazine formulations.